Jane Summerfield

Solicitor, Hogan Lovells

Jane Summerfield is Co-Head of our Life Sciences and Health Care sector and leads the Hogan Lovells life sciences regulatory and commercial practice in London. She advises life sciences companies on a wide range of regulatory matters, including clinical trials, early access, marketing authorisations, manufacturing and distribution licences, CE/UKCA marking, digital health, advertising and marketing activities, HCP compliance, and pricing and reimbursement.

Jane also advises on commercial contractual arrangements, including consultancy, sponsorship, co-promotion, collaboration, manufacturing, distribution, services, quality and pharmacovigilance agreements.

Jane works with clients to resolve issues with UK enforcement authorities and regulatory bodies, including the Medicines and Healthcare products Regulatory Agency (MHRA), Prescription Medicines Code of Practice Authority (PMCPA) and Advertising Standards Authority (ASA).

Jane combines a scientific background with deep regulatory knowledge and a commercial approach, providing "clear responses with business impact".

Contributed to

4

An introduction to the regulation of medical devices—EU Directives regime

Practice notes

This Practice Note provides an overview of the regulatory framework set out by Directive 93/42/EEC on medical devices (MDD), Directive 90/385/EEC on active implantable medical devices (AIMDD), which were applicable until 25 May 2021, and Directive 98/79/EC on in vitro diagnostic medical devices (IVDD), which applied until 25 May 2022, altogether the MD Directives. The MD Directives still are relevant to ‘legacy’ devices which were authorised in accordance with them for placement on the EEA market before the new regulatory regime began its application. The MD Directives will continue to be relevant as a reference for a number of years in relation to certain legacy devices for varying time periods in accordance with transitional provisions. This Practice Note explains how devices were classified, assessed (by completion of a conformity assessment) and CE marked under the MD Directives. It also considers the advertising and promotion of medical devices, counterfeit medical devices, 3D printing and mobile health.

Life Sciences

EU regulatory data protection

Practice notes

This Practice Note explains the concept of regulatory data protection (RDP), also known as ‘data exclusivity’, provides guidance on how RDP works in practice and the impact it has on the entry into the EU market of generic and biosimilar medicinal products.

EU Law

Falsified medicines

Practice notes

This Practice Note explores the changes introduced to the regulation of medicinal products in the EU by the Falsified Medicines Directive to combat the increase in the incidence of falsified medicinal products. First, the Practice Note considers what is meant by the term ‘falsified medicinal product’, before looking at the measures introduced by the Falsified Medicines Directive: greater control of active substances, obligations for actors in the supply chain, the introduction of safety features on the packaging of medicinal products and the common logo for websites selling medicinal products. This Practice Note also provides an overview of the UK regime for falsified medicines.

Life Sciences

Regulatory data protection

Practice notes

This Practice Note explains the concept of regulatory data protection (RDP), also known as ‘data exclusivity’, provides guidance on how RDP works in practice and the impact it has on the entry into the market of generic and biosimilar medicinal products.

Life Sciences